GI Innovation news
- Aim for IPO, in the 4Q of 2022 through Unicorn special track
- Clinical trial data from the phase 1/2 study of GI-101 monotherapy and combination therapy with Keytruda of GI-101 and phase 1 study of GI-301 to be released by end of 2022
GI Innovation, Inc., an innovative new drug development company announced its submission of a preliminary application for KOSDAQ listing on April 20th. The representative listed organizers are NH Investment &
- Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey
- Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment
GI Innovation, an innovative new drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKe
-GI Innovation·GI Cell, respectively establishing a cell therapy center at Severance Hospital·Songdo Severance Hospital(tentative named)
-Establishment of the seamless process for research, production, clinical trials, Regulatory affair (RA), and etc. of advanced biopharmaceutical
GI Innovation, a new innovative drug development company, announced on March 3rd that it has signed MoU with its allied company, GI Cell and Yonsei University health System (YUHS) for e
- Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey
- Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment
GI Innovation, a new innovative drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKey, a Gl
GI Innovation, Inc., (CEO, Jun Ho Hong) announced that GI Innovation signed a clinical supply collaboration agreement with global biopharmaceutical company AstraZeneca for development of GI-101 and Imfinzi® combination therapy.
Under this agreement, GI Innovation and AstraZeneca will conduct a clinical trial assessing triplet combination regimen of GI-101, Imfinzi® (durvalumab) and chemotherapy for the treatment of small cell lung cancer, gastric/gast